Read by QxMD icon Read


Fumihito Hirai, Tetsuya Ishida, Fuminao Takeshima, Shojiro Yamamoto, Ichiro Yoshikawa, Shinya Ashizuka, Haruhiko Inatsu, Keiichi Mitsuyama, Suketo Sou, Ryuichi Iwakiri, Ryoichi Nozaki, Hidehisa Ohi, Motohiro Esaki, Mitsuo Iida, Toshiyuki Matsui
BACKGROUND AND AIMS: The aim of this study was to clarify the additional effect of a concomitant elemental diet (ED) for patients with Crohn's disease (CD) on maintenance anti-TNF-alfa antibody (anti-TNF). METHODS: CD patients who received anti-TNF induction therapy were enrolled. Patients who achieved clinical response (defined as delta CDAI>70 and CDAI<200) at 10-14 weeks after the start of infliximab or adalimumab were included. Eligible patients took a tolerability test of ED (900 kcal/day) for 3 days...
June 23, 2018: Journal of Gastroenterology and Hepatology
Z Chen, M Tang, D Huang, W Jiang, M Li, H Ji, J Park, B Xu, L J Atchison, G A Truskey, K W Leong
Human cell-based 3D tissue constructs play an increasing role in disease modeling and drug screening. Inflammation, atherosclerosis, and many autoimmune disorders involve the interactions between immune cells and blood vessels. However, it has been difficult to image and model these interactions under realistic conditions. In this study, we fabricated a perfusion and imaging chamber to allow the real-time visualization of leukocyte perfusion, adhesion, and migration inside a tissue-engineered blood vessel (TEBV)...
June 21, 2018: Lab on a Chip
Siddharth Singh, James A Proudfoot, Parambir S Dulai, Vipul Jairath, Mathurin Fumery, Ronghui Xu, Brian G Feagan, William J Sandborn
OBJECTIVES: 5-aminosalicylates (5-ASA) are frequently continued in patients with moderate-severe ulcerative colitis (UC), even after escalation to biologic agents, without evaluation of the benefit of this approach. We conducted an individual participant data (IPD) pooled analysis of trials of infliximab and golimumab in UC, to evaluate whether concomitant use of 5-ASA modifies clinical outcomes among anti-tumor necrosis factor (TNF)-α-treated patients. METHODS: We included IPD from five trials of infliximab and golimumab in patients with moderate-severe UC (ACT-1 and -2, PURSUIT-SC, PURSUIT-M, NCT00336492)...
June 21, 2018: American Journal of Gastroenterology
L King, I Tsilioni, T C Theoharides
Cachexia is a wasting condition associated with late stages of many chronic illnesses and may be present in up to 80% of patients with advanced cancers. Cachexia is a metabolic derangement resulting in a disturbance to the homeostasis of muscle breakdown and synthesis, favoring catabolism and muscle loss. Despite making strides in treating cancer itself, there have been no major advances in the treatment of cachexia pharmacologically or nutritionally. Clinical trials using anti-TNF biologics and thalidomide have largely failed...
May 2018: Journal of Biological Regulators and Homeostatic Agents
Yesim Ozguler, Yusuf Yazici, Gulen Hatemi, Koray Tascilar, Hasan Yazici
No abstract text is available yet for this article.
June 19, 2018: Pharmacoepidemiology and Drug Safety
S Singh, M Fumery, W J Sandborn, M H Murad
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe Crohn's disease (CD). AIM: We assessed comparative efficacy and safety of first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor [TNF]-α) agents) biologic therapy for moderate-severe CD, through a systematic review and network meta-analysis, and appraised quality of evidence (QoE) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach...
June 19, 2018: Alimentary Pharmacology & Therapeutics
Monica S M Persson, Aliya Sarmanova, Michael Doherty, Weiya Zhang
Objectives: The role of inflammation in OA is controversial and it is unclear whether suppressing inflammation with conventional or biologic DMARDs is effective. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to compare DMARDs with placebo in participants with symptomatic OA. Methods: Databases (Medline, Embase, Allied and Complementary Medicine Database, Web of Science and Cochrane Library), conference abstracts and ClinicalTrials...
June 16, 2018: Rheumatology
Christoffer Soendergaard, Jakob Benedict Seidelin, Casper Steenholdt, Ole Haagen Nielsen
Objectives: Characterise the circulating inflammatory cytokine pattern among patients failing consecutive anti-tumour necrosis factor (anti-TNF) and anti-integrin treatments to identify predictors of response. Methods: A retrospective single-centre cohort study of 28 patients with inflammatory bowel disease (IBD) receiving anti-integrin therapy (vedolizumab) subsequent to the failure of anti-TNF treatment was conducted. Blood samples were obtained immediately prior to initiation of vedolizumab therapy, and the response to treatment was evaluated after completion of the 14-week induction regimen...
2018: BMJ Open Gastroenterology
Arne Bokemeyer, Nicolas Tentrop, Peter J Barth, Frank Lenze, Karin Hengst, Johannes Kleinheinz, Dominik Bettenworth
BACKGROUND: Crohn's Disease (CD) is typically characterized by abdominal symptoms, however, besides gastrointestinal symptoms, CD patients may suffer from extraintestinal manifestations which are far less common and medical treatment can be challenging. CASE PRESENTATION: We report about a 34-year-old Crohn's Disease (CD) patient in clinical remission under adalimumab therapy who presented in the clinic for Cranio-Maxillo Surgery due to severe pain in the mandibular area...
June 18, 2018: BMC Gastroenterology
Cynthia H Seow, Niels Vande Casteele, Remo Panaccione
No abstract text is available yet for this article.
June 14, 2018: Journal of Crohn's & Colitis
Abhijeet Yadav, Satya Kurada, Joshua Foromera, Kenneth R Falchuk, Joseph D Feuerstein
BACKGROUND: Long-term inflammatory complications of IPAA include Crohn's Disease (CD) or "CD-like" (CDL) condition. We performed a meta-analysis to evaluate the efficacy of anti-tumor necrosis factor (anti-TNF) with or without immunomodulator (IM) therapy in this group of patients. METHODS: Literature databases were searched from inception to October 4, 2017. Further searches using references from papers of interest were conducted and, abstracts from major GI conferences were searched...
May 30, 2018: Digestive and Liver Disease
Blanca Martínez Andrés, Violeta Sastre Lozano, José Francisco Sánchez Melgarejo
Sweet syndrome is a common extraintestinal manifestation in inflammatory bowel disease (IBD). In this research, a 42-year-old man case with colon Crohn's disease is been described. After failure with two anti-TNF therapies, in treatment with azathioprim, it was decided to start a therapeutic target change to Vedolizumab due to a severe outbreak refractory to corticosteroids. 24 hours after the infusion of the new drug, skin lesions appear along with leukocytes with neutrophilia, all suggestive of sweet syndrome later confirmed by histology...
June 14, 2018: Revista Española de Enfermedades Digestivas
Bufang Xu, Mingjuan Zhou, Jingwen Wang, Dan Zhang, Feng Guo, Chenchen Si, Peter C K Leung, Aijun Zhang
STUDY QUESTION: Is allograft inflammatory factor-1 (AIF-1), a cytokine associated with inflammation and allograft rejection, aberrantly elevated in in vitro fertilization (IVF) cycles with gonadotropin-releasing hormone (GnRH) antagonist protocol with potential effects on endometrial receptivity? SUMMARY ANSWER: Our findings indicated AIF-1 is increased in IVF cycles with GnRH antagonist protocol and mediates greater TNF-α expression during implantation phase, which may be unfavorable for embryo implantation...
June 12, 2018: Human Reproduction
Przemyslaw J Kotyla
Treatment with anti-TNF-&alpha; (tumor necrosis factor), one of the pivotal cytokines, was introduced to clinical practice at the end of last century and revolutionized the treatment of rheumatoid arthritis (RA) as well as many other inflammatory conditions. Such a treatment may however bring many safety issues regarding infections, tuberculosis, as well as cardiovascular diseases, including heart failure. Given the central role of proinflammatory cytokines in RA, atherosclerosis, and congestive heart failure (CHF), such a treatment might result in better control of the RA process on the one side and improvement of heart function on the other...
June 12, 2018: International Journal of Molecular Sciences
Gia Deyab, Ingrid Hokstad, Jan Aaseth, Milada Cvancarova Småstuen, Jon Elling Whist, Stefan Agewall, Torstein Lyberg, Dag Tveiten, Gunnbjorg Hjeltnes, Kazem Zibara, Ivana Hollan
OBJECTIVES: The reason for increased cardiovascular risk in inflammatory arthritis (IA) is unclear. Interestingly, selenium-deficiency is suspected to contribute to the development of cardiovascular disease (CVD) in the general population. Although the reference range of serum selenium (s-selenium) is 50-120 μg/L, there are indications that levels up to 85 μg/L might not be sufficient for optimal cardioprotection. Our aim was to examine s-selenium levels in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS), to evaluate the effect of anti-rheumatic treatment on s-selenium levels, and to assess relationships between s-selenium levels and clinical and laboratory parameters including markers of disease activity and CVD risk...
September 2018: Journal of Trace Elements in Medicine and Biology
Aichao Shi, Xiaoping Zhang, Fang Xiao, Lin Zhu, Weiming Yan, Meifang Han, Xiaoping Luo, Tao Chen, Qin Ning
HBV surface antigen (HBsAg) reduction is well observed in chronic hepatitis B (CHB) patients treated with pegylated interferon-alpha-2a (Peg-IFNα). However, the mechanism of HBsAg suppression has not been fully elucidated. Twenty-seven of 55 Entecavir-treated CHB e antigen positive patients were switched to Peg-IFNα treatment (Group A) whereas 28 patients continued entecavir treatment (Group B). The percentage or absolute number of CD56bright /CD56dim NK cells, expression of receptors and cytokines were evaluated by flow cytometry for 48 weeks and correlated with treatment efficacy...
June 11, 2018: Journal of Viral Hepatitis
Hossein Safarpour, Morteza Shahmirzaie, Elham Rezaee, Mahmood Barati, Mohammad Reza Safarnejad, Farshad H Shirazi
Tumor necrosis factor alpha (TNF-α) expression amplifies to excess amounts in several disorders such as rheumatoid arthritis and psoriasis. Although, Anti-TNF biologics have revolutionized the treatment of these autoimmune diseases, formation of anti-drug antibodies (ADA) has dramatically affected their use. The next generation antibodies ( e.g. Fab, scFv) have not only reduced resulted immunogenicity, but also proved several benefits including better tumor penetration and more rapid blood clearance. Using affinity selection procedures in this study, a scFv antibody clone was isolated from naïve Tomlinson I phage display library that specifically recognizes and binds to TNF-α...
2018: Iranian Journal of Pharmaceutical Research: IJPR
Jim O'Connell, Cathy Rowan, Roisin Stack, Grace Harkin, Vikrant Parihar, Grace Chan, Niall Breslin, Garret Cullen, Cara Dunne, Laurence Egan, Gavin Harewood, Jan Leyden, Finbar MacCarthy, Padraic MacMathuna, Nasir Mahmud, Susan McKiernan, Deirdre McNamara, Hugh Mulcahy, Frank Murray, Anthony O'Connor, Aoibhlinn O'Toole, Stephen Patchett, Barbara Ryan, Juliette Sheridan, Eoin Slattery, Glen Doherty, David Kevans
BACKGROUND AND AIMS: Golimumab (GLB) is an antitumour necrosis factor-α (anti-TNF) therapy that has shown efficacy as induction and maintenance therapy for ulcerative colitis (UC). We aimed to describe the outcome of GLB therapy for UC in a real-world clinical practice. PATIENTS AND METHODS: Consecutive patients receiving GLB for UC in six Irish Academic Medical Centres were identified. The primary study endpoint was the 6-month corticosteroid-free remission rate...
June 6, 2018: European Journal of Gastroenterology & Hepatology
K Herfurth, M Busch, H J Gröne, G Wolf
Treatment with tumor necrosis factor alpha (TNF-α) inhibitors is a well-established therapeutic strategy for various autoimmune diseases. However, little is known about renal complications and possible causality of renal injury due to this treatment. The following case of a patient with psoriasis demonstrates the difficulties in classifying renal complications of anti-TNF-α therapy versus kidney involvement caused by the underlying disease.
June 5, 2018: Der Internist
Ye He, Amr H Sawalha
PURPOSE OF REVIEW: Rapid introduction of newly developed drugs in the absence of clear understanding of the pathophysiologic mechanisms behind drug-induced lupus erythematosus (DILE) can sometimes make DILE difficult to recognize in clinical practice. The purpose of this review is to summarize drugs most recently reported to be involved in DILE and discuss the current landscape of diverse mechanisms involved. RECENT FINDINGS: A large number of proton pump inhibitor (PPI)-induced subacute cutaneous lupus erythematosus cases have been reported, suggesting a shift over time in the spectrum of drugs implicated in DILE...
June 4, 2018: Current Opinion in Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"